Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a 'don't eat me' signal that protects cancer cells from being attacked by the immune system.
The FDA has approved GlaxoSmithKline's latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the patient population eligible for treatment with the drug.
Merck & Co is looking at a decision from the FDA in December on its application to market Keytruda as a post-surgery treatment for people with kidney cancer, after a priority review.
Gilead Sciences' Kite Pharma has mapped out another route to the development of allogeneic or 'off-the-shelf' cell therapies for cancer, using technology developed by Appia Bio, a US startu
Bristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy market, and has just reinforced its position with an EU approval in t